Final month marked continued progress as digital well being strikes into its subsequent part — from AI increasing into drug discovery and core infrastructure to new federal pathways accelerating gadget entry and home-based care. Collectively, these shifts sign a turning level towards real-world scale.
Right here’s a better have a look at the important thing developments driving that momentum.
Expertise, Information, and Insights
CMS Launches First Wave of HealthTech Ecosystem Instruments, Quick‑Monitoring a Absolutely Digital, Affected person‑Centered Well being System
CMS launched the primary wave of its HealthTech Ecosystem initiative, rolling out new interoperable instruments, a Medicare app library, and patient-facing purposes designed to streamline how people entry and handle their well being knowledge. The hassle brings collectively tons of of organizations aligned round shared requirements for id, safety, and knowledge trade.
Learn the total CMS press launch right here >>
Self-Powering Sensible Materials Sign Subsequent Section of Wearables
Researchers are creating sensor-embedded materials that may monitor well being metrics like coronary heart charge, respiration, and temperature whereas producing energy from physique warmth and motion. The expertise might be built-in into on a regular basis clothes, yoga mats, wristbands, and even bedsheets, enabling steady monitoring with out the necessity for charging or standalone units.
This factors to a broader shift from device-based wearables to ambient well being monitoring, the place knowledge assortment turns into passive, always-on, and embedded into day by day life.
Learn the total TechRadar article right here >>
OpenAI Companions with Novo Nordisk to Speed up AI-Pushed Drug Discovery
Novo Nordisk introduced a strategic partnership with OpenAI to combine superior AI throughout its drug growth pipeline, utilizing large-scale knowledge evaluation to determine new drug candidates and speed up time from analysis to affected person supply. The collaboration can even lengthen into manufacturing, provide chain, and business operations, signaling a broader shift towards end-to-end AI integration in pharma.
Learn the total MobiHealthNews article right here >>
Coverage and Regulatory
FDA to Evaluate Peptides for Potential Compounding Entry in July Advisory Assembly
The FDA introduced it’ll convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23–24 to guage whether or not seven peptides ought to be added to the 503A bulk drug substances record. A key step that may permit licensed 503A pharmacies to compound them with a legitimate, patient-specific prescription. The substances below assessment embody peptides tied to circumstances like weight problems, wound therapeutic, irritation, and sleep problems.
Learn the total FDA announcement right here >>
FDA Launches READI-House Innovation Problem to Advance House-Primarily based Care
The FDA launched the READI-House Innovation Problem, a brand new initiative geared toward accelerating growth of medical units designed to be used within the house to cut back hospital readmissions. This system invitations innovators to submit applied sciences that assist sufferers and caregivers following acute care episodes, with a concentrate on bettering outcomes and stopping avoidable returns to the hospital.
Learn the total FDA announcement right here >>
CMS and FDA announce RAPID Pathway to Speed up Medical Machine Protection
CMS and the FDA launched the RAPID (Regulatory Alignment for Predictable and Speedy Machine) protection pathway, designed to hurry up Medicare entry to breakthrough medical units by aligning regulatory approval and reimbursement processes. This system allows earlier collaboration between regulators and producers in order that medical proof generated for FDA assessment also can assist Medicare protection selections.
Learn the total FDA announcement right here >>
DOJ Strikes to Reclassify Medical Marijuana, Increasing Entry and Analysis Pathways
The Division of Justice introduced it’ll place FDA-approved and state-regulated medical marijuana merchandise into Schedule III, a transfer that acknowledges their medical use whereas sustaining federal oversight. The choice expands entry to accredited therapies, helps state applications, and allows broader analysis into security and efficacy — alongside an expedited course of to guage full federal rescheduling.
Learn the total DOJ announcement right here >>
Learn extra at Openloop!
